Greenwich LifeSciences Updates CEO Interviews and Key Events, Presents Flamingo-01 Trial Data at Major Conferences.

Greenwich LifeSciences CEO has been featured on Bloomberg TV, Noble Virtual Conference, and Charles Schwab Network, discussing the company's progress in developing immunotherapy GLSI-100 for breast cancer recurrence prevention. The company has also presented Flamingo-01 trial data at major conferences, including ASCO and ESMO. GLSI has engaged with investors at key conferences, reinforcing its commitment to transparency and growth.

Greenwich LifeSciences (NASDAQ: GLSI), a clinical-stage biopharmaceutical company, has been actively promoting its immunotherapy GLSI-100 for breast cancer recurrence prevention through a series of high-profile interviews and presentations. The company's CEO has been featured on Bloomberg TV, the Noble Virtual Conference, and the Charles Schwab Network, providing updates on the company's progress and its commitment to innovation.

Additionally, Greenwich LifeSciences has been presenting its Flamingo-01 trial data at major industry conferences, including the San Antonio Breast Cancer Symposium, ESMO Breast Conference, and ASCO. The company's participation in these conferences underscores its dedication to transparency and scientific rigor.

Greenwich LifeSciences has also engaged with investors at key conferences, such as the BIO CEO & Investor Conference, H.C. Wainwright BioConnect, and the Jefferies Global Healthcare Conference. These engagements highlight the company's commitment to fostering growth and maintaining open lines of communication with its stakeholders.

Greenwich LifeSciences is focused on developing GLSI-100, an immunotherapy designed to prevent breast cancer recurrences in patients who have previously undergone surgery. The company's Phase III clinical trial, FLAMINGO-01, is currently underway and aims to evaluate the safety and efficacy of GLSI-100 in HER2 positive breast cancer patients. The trial is led by Baylor College of Medicine and involves clinical sites from university-based hospitals and academic and cooperative networks across the US and Europe, with plans to expand globally.

For more information on Greenwich LifeSciences and its clinical trials, please visit the company's website at [Greenwich LifeSciences](https://greenwichlifesciences.com/) and follow the company's Twitter account at [GreenwichLS](https://twitter.com/GreenwichLS).

References:
[1] https://www.stocktitan.net/news/GLSI/greenwich-life-sciences-provides-update-on-ceo-interviews-corporate-83za57qvkw1v.html